Early versus delayed initiation of entacapone in levodopa‐treated patients with Parkinson’s disease: a long‐term, retrospective analysis
Identifieur interne : 000B04 ( Main/Exploration ); précédent : 000B03; suivant : 000B05Early versus delayed initiation of entacapone in levodopa‐treated patients with Parkinson’s disease: a long‐term, retrospective analysis
Auteurs : H. Nissinen [Finlande] ; M. Kuoppam Ki [Finlande] ; M. Leinonen [Suède] ; A. H. Schapira [Royaume-Uni]Source :
- European Journal of Neurology [ 1351-5101 ] ; 2009-12.
English descriptors
- KwdEn :
Abstract
Background: We analysed data from three clinical trials in Parkinson’s disease (PD) patients with wearing‐off to determine whether early enhancement of levodopa therapy with entacapone can lead to better long‐term outcomes than delayed entacapone treatment. Methods: Post‐hoc analysis of pooled data from three randomized, double‐blind, placebo‐controlled studies and their long‐term, open‐label extension phases. In all three studies, patients on levodopa/dopa‐decarboxylase inhibitor (DDCI) were first randomized to entacapone (‘early‐start’ group) or placebo (‘delayed‐start’ group) for the initial 6‐month double‐blind phase, after which all patients received open‐label levodopa/DDCI and entacapone treatment for up to 5 years. Results: A total of 488 PD patients with wearing‐off were included in the analysis. A statistically significant benefit of early initiation of levodopa/DDCI and entacapone was found, with an improvement in Unified Parkinson’s Disease Rating Scale Part III (motor) score of −1.66 (95% confidence intervals [−3.01, −0.31]) points compared with the delayed‐start treatment group (P < 0.05). Levodopa/DDCI and entacapone therapy was well tolerated. There was no excess of dyskinesia in the early‐start group. Conclusions: These data suggest that early rather than delayed addition of entacapone to levodopa/DDCI in PD patients with wearing‐off provides a modest clinical benefit over levodopa/DDCI that is maintained for up to 5 years.
Url:
DOI: 10.1111/j.1468-1331.2009.02726.x
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Early versus delayed initiation of entacapone in levodopa‐treated patients with Parkinson’s disease: a long‐term, retrospective analysis</title><author><name sortKey="Nissinen, H" sort="Nissinen, H" uniqKey="Nissinen H" first="H." last="Nissinen">H. Nissinen</name></author><author><name sortKey="Kuoppam Ki, M" sort="Kuoppam Ki, M" uniqKey="Kuoppam Ki M" first="M." last="Kuoppam Ki">M. Kuoppam Ki</name></author><author><name sortKey="Leinonen, M" sort="Leinonen, M" uniqKey="Leinonen M" first="M." last="Leinonen">M. Leinonen</name></author><author><name sortKey="Schapira, A H" sort="Schapira, A H" uniqKey="Schapira A" first="A. H." last="Schapira">A. H. Schapira</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:16F213EBB8D3A357753F7CF40F76BADFB5C62FE5</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1111/j.1468-1331.2009.02726.x</idno><idno type="url">https://api.istex.fr/document/16F213EBB8D3A357753F7CF40F76BADFB5C62FE5/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000F09</idno><idno type="wicri:Area/Main/Curation">000D37</idno><idno type="wicri:Area/Main/Exploration">000B04</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Early versus delayed initiation of entacapone in levodopa‐treated patients with Parkinson’s disease: a long‐term, retrospective analysis</title><author><name sortKey="Nissinen, H" sort="Nissinen, H" uniqKey="Nissinen H" first="H." last="Nissinen">H. Nissinen</name><affiliation wicri:level="1"><country xml:lang="fr">Finlande</country><wicri:regionArea>Orion Pharma, Espoo</wicri:regionArea><wicri:noRegion>Espoo</wicri:noRegion></affiliation></author><author><name sortKey="Kuoppam Ki, M" sort="Kuoppam Ki, M" uniqKey="Kuoppam Ki M" first="M." last="Kuoppam Ki">M. Kuoppam Ki</name><affiliation wicri:level="3"><country xml:lang="fr">Finlande</country><wicri:regionArea>Orion Pharma, Turku</wicri:regionArea><placeName><settlement type="city">Turku</settlement><region type="région" nuts="2">Finlande occidentale</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Neurology, Turku University Hospital, University of Turku, Turku</wicri:regionArea><placeName><settlement type="city">Turku</settlement><region type="région" nuts="2">Finlande occidentale</region></placeName></affiliation></author><author><name sortKey="Leinonen, M" sort="Leinonen, M" uniqKey="Leinonen M" first="M." last="Leinonen">M. Leinonen</name><affiliation wicri:level="1"><country xml:lang="fr">Suède</country><wicri:regionArea>4Pharma AB, Kista</wicri:regionArea><wicri:noRegion>Kista</wicri:noRegion></affiliation></author><author><name sortKey="Schapira, A H" sort="Schapira, A H" uniqKey="Schapira A" first="A. H." last="Schapira">A. H. Schapira</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University Department of Clinical Neurosciences, Institute of Neurology, University College London, National Hospital for Neurology and Neurosurgery and Royal Free Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">European Journal of Neurology</title><idno type="ISSN">1351-5101</idno><idno type="eISSN">1468-1331</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2009-12">2009-12</date><biblScope unit="volume">16</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1305">1305</biblScope><biblScope unit="page" to="1311">1311</biblScope></imprint><idno type="ISSN">1351-5101</idno></series><idno type="istex">16F213EBB8D3A357753F7CF40F76BADFB5C62FE5</idno><idno type="DOI">10.1111/j.1468-1331.2009.02726.x</idno><idno type="ArticleID">ENE2726</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1351-5101</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson’s disease</term><term>entacapone</term><term>levodopa</term><term>wearing‐off</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background: We analysed data from three clinical trials in Parkinson’s disease (PD) patients with wearing‐off to determine whether early enhancement of levodopa therapy with entacapone can lead to better long‐term outcomes than delayed entacapone treatment. Methods: Post‐hoc analysis of pooled data from three randomized, double‐blind, placebo‐controlled studies and their long‐term, open‐label extension phases. In all three studies, patients on levodopa/dopa‐decarboxylase inhibitor (DDCI) were first randomized to entacapone (‘early‐start’ group) or placebo (‘delayed‐start’ group) for the initial 6‐month double‐blind phase, after which all patients received open‐label levodopa/DDCI and entacapone treatment for up to 5 years. Results: A total of 488 PD patients with wearing‐off were included in the analysis. A statistically significant benefit of early initiation of levodopa/DDCI and entacapone was found, with an improvement in Unified Parkinson’s Disease Rating Scale Part III (motor) score of −1.66 (95% confidence intervals [−3.01, −0.31]) points compared with the delayed‐start treatment group (P < 0.05). Levodopa/DDCI and entacapone therapy was well tolerated. There was no excess of dyskinesia in the early‐start group. Conclusions: These data suggest that early rather than delayed addition of entacapone to levodopa/DDCI in PD patients with wearing‐off provides a modest clinical benefit over levodopa/DDCI that is maintained for up to 5 years.</div></front></TEI><affiliations><list><country><li>Finlande</li><li>Royaume-Uni</li><li>Suède</li></country><region><li>Angleterre</li><li>Finlande occidentale</li><li>Grand Londres</li></region><settlement><li>Londres</li><li>Turku</li></settlement></list><tree><country name="Finlande"><noRegion><name sortKey="Nissinen, H" sort="Nissinen, H" uniqKey="Nissinen H" first="H." last="Nissinen">H. Nissinen</name></noRegion><name sortKey="Kuoppam Ki, M" sort="Kuoppam Ki, M" uniqKey="Kuoppam Ki M" first="M." last="Kuoppam Ki">M. Kuoppam Ki</name><name sortKey="Kuoppam Ki, M" sort="Kuoppam Ki, M" uniqKey="Kuoppam Ki M" first="M." last="Kuoppam Ki">M. Kuoppam Ki</name></country><country name="Suède"><noRegion><name sortKey="Leinonen, M" sort="Leinonen, M" uniqKey="Leinonen M" first="M." last="Leinonen">M. Leinonen</name></noRegion></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Schapira, A H" sort="Schapira, A H" uniqKey="Schapira A" first="A. H." last="Schapira">A. H. Schapira</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B04 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000B04 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:16F213EBB8D3A357753F7CF40F76BADFB5C62FE5
|texte= Early versus delayed initiation of entacapone in levodopa‐treated patients with Parkinson’s disease: a long‐term, retrospective analysis
}}
| This area was generated with Dilib version V0.6.23. |  |